Filer Snapshot

NAVIDEA BIOPHARMACEUTICALS, INC.

CIK 0000810509. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

1,465

Latest filing

05 Feb 2024

Industry

In Vitro and in Vivo Diagnostic Substances

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: SEC filing timeline only. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Go to filings Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

—

No recent parsed 13D/G stake row for this CIK.

Browse 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Schedule 13D/G

SC 13D/A filed on 05 Feb 2024 for CIK 0000810509.

View source filing
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
In Vitro and in Vivo Diagnostic Substances (Office of Life Sciences)
Business address
4995 Bradenton Avenue, Suite 240, Dublin, OH, 43017
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Incorporated in
DE
Fiscal year end
31 December
Former names on EDGAR
NEOPROBE CORP (to 30 Dec 2011)

Filer intelligence

What SEC filings say about NAVIDEA BIOPHARMACEUTICALS, INC.

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

SEC source mix

Counts show available parsed rows, not one combined ownership total.

No XML rows yet
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

No parsed ownership summary yet

We still show the SEC filing timeline below. The intelligence summary will populate when parsed 13F, 13D/G, or Forms 3/4/5 data exists for this CIK.

Latest update

What changed recently for NAVIDEA BIOPHARMACEUTICALS, INC.

New fact period available

Latest financial period: Q3 2023. Open the source-backed page to inspect the fresh filing or facts context.

Update date

14 Nov 2023

Page type

Company facts

Latest period

Q3 2023

SEC-backed company facts were refreshed from filings filed on 14 Nov 2023.

Open company facts Browse recent public updates

Benchmark Context

Benchmark context for this company

NAVIDEA BIOPHARMACEUTICALS, INC. has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest financial period: Q3 2023. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 14 Nov 2023.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0000810509 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
1,465
First seen
07 Feb 1995
Latest filing
05 Feb 2024
Entity
Company

Observed form types

SC 13D/A EFFECT S-8 POS POS AM 15-12G 25-NSE S-8 4 8-K 10-Q +35 more

CIK-linked evidence first

NAVIDEA BIOPHARMACEUTICALS, INC. SEC filings NAVIDEA BIOPHARMACEUTICALS, INC. insider transactions NAVIDEA BIOPHARMACEUTICALS, INC. company facts Open SEC filing index

Industry context: In Vitro and in Vivo Diagnostic Substances.

Latest Filings

Showing the latest 12 of 949 SEC filings for NAVIDEA BIOPHARMACEUTICALS, INC..

Open full filing history
SC 13D/A File 005-43603

SC 13D/A

Filing date
05 Feb 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-274246

EFFECT filing

Filing date
31 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-262691

EFFECT filing

Filing date
31 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-252847

EFFECT filing

Filing date
31 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-248404

EFFECT filing

Filing date
31 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-235762

EFFECT filing

Filing date
31 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 POS File 333-276266

FORM S-8 POS

Filing date
26 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 POS File 333-268956

FORM S-8 POS

Filing date
26 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 POS File 333-250078

FORM S-8 POS

Filing date
26 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 POS File 333-228960

FORM S-8 POS

Filing date
26 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
POS AM File 333-235762

FORM POS AM

Filing date
26 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 POS File 333-198716

FORM S-8 POS

Filing date
26 Jan 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .